Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Update

Avenue Therapeutics, Inc. (NASDAQ:ATXI) saw a large decline in short interest in the month of December. As of December 31st, there was short interest totalling 22,500 shares, a decline of 35.9% from the December 15th total of 35,100 shares. Based on an average trading volume of 49,600 shares, the days-to-cover ratio is presently 0.5 days. Approximately 1.3% of the company’s shares are sold short.

Hedge Funds Weigh In On Avenue Therapeutics

A hedge fund recently bought a new position in Avenue Therapeutics stock. Moss Adams Wealth Advisors LLC acquired a new position in Avenue Therapeutics, Inc. (NASDAQ:ATXI) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 11,000 shares of the company’s stock, valued at approximately $27,000. Moss Adams Wealth Advisors LLC owned approximately 1.17% of Avenue Therapeutics as of its most recent SEC filing. 17.34% of the stock is owned by institutional investors.

Avenue Therapeutics Stock Performance

ATXI stock traded up $0.10 during midday trading on Friday, reaching $1.85. The company’s stock had a trading volume of 43,222 shares, compared to its average volume of 81,738. Avenue Therapeutics has a 1 year low of $1.60 and a 1 year high of $15.00. The firm has a market capitalization of $3.79 million, a price-to-earnings ratio of 0.10 and a beta of -0.27. The stock has a fifty day simple moving average of $1.91 and a two-hundred day simple moving average of $2.40.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.